RxDoctor Payments Data

Fangqin Li, MD

Family Medicine · Stony Brook, NYNPI 1427198076

Payments from drug & device makers

$2,405in general payments, 2019–2025

Across 115 payments — averaging $20.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$396
  • AbbVie$235
  • Amgen$232
  • Lilly USA, LLC$195
  • Novartis$178
  • Pfizer$165
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$2,37799%
  • Education$281%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,405 in reported general payments places this provider in the 75th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$361,461
Medicare patients
216
Services billed
4,496

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban92$83,501
TrulicityDulaglutide45$60,931
JardianceEmpagliflozin38$50,046
FarxigaDapagliflozin Propanediol42$43,162
OzempicSemaglutide25$31,249
JanuviaSitagliptin Phosphate19$23,921
JanumetSitagliptin Phos/Metformin Hcl11$17,004
Lantus SolostarInsulin Glargine,hum.Rec.Anlog38$7,589
Diclofenac Epolamine21$7,494
BelsomraSuvorexant17$7,163
VascepaIcosapent Ethyl12$6,934
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$6,660
Novolog FlexpenInsulin Aspart28$5,790
Metoprolol Succinate208$3,961
Levothyroxine Sodium242$3,944

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$165$83,50192 claims
Lilly USA, LLCTrulicity$195$60,93145 claims
Boehringer IngelheimJardiance$159$50,04638 claims
MerckJanuvia, Janumet, Belsomra$88$48,08947 claims
AstraZenecaFarxiga$396$43,16242 claims
Novo NordiskOzempic$35$31,24925 claims
AbbVieSynthroid$235$1,62827 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,321 family medicine providers in New York.

Other family medicine in Stony Brook

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →